8QQ Stock Chart & Stats
€5.06
€0.02(0.40%)
At close: 4:00 PM EDT
€5.06
€0.02(0.40%)
Day’s Range― - ―
52-Week Range€2.49 - €7.65
Previous CloseN/A
Volume130.00
Average Volume (3M)822.00
Market Cap
€1.51B
Enterprise Value€668.18
Total Cash (Recent Filing)€504.73M
Total Debt (Recent Filing)€140.18M
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Aug 05, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.48
Shares Outstanding305,375,400
10 Day Avg. Volume663
30 Day Avg. Volume822
Financial Highlights & Ratios
PEG Ratio0.64
Price to Book (P/B)1.06
Price to Sales (P/S)13.60
P/FCF Ratio-5.87
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€9.12Price Target Upside80.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.52
Revenue Forecast (FY)€27.92M
Bulls Say, Bears Say
Bulls Say
Strong Liquidity RunwayA roughly $655M liquidity pool supports at least three years of pipeline investment, reducing near-term financing risk. This durable cash buffer allows the company to advance multiple clinical programs, invest in discovery/manufacturing capabilities, and negotiate longer-term partnerships without urgent dilution.
Validated Discovery Platform Via PartnershipsStrategic collaborations (Vertex, Jazz) provide non-dilutive upfronts, milestones, and potential royalties while validating AbCellera's integrated T-cell engager and antibody discovery platform. Such partnerships de-risk commercialization pathways and create recurring service and royalty opportunities over the medium term.
Clear Pipeline Cadence And Clinical CatalystsA defined clinical milestone schedule (Phase II readout for ABCL635, Phase I readout for ABCL575) provides durable value-creation points. Successfully converting these catalysts supports transition from discovery services to internal-product economics and strengthens long-term royalty and licensing prospects.
Bears Say
Persistent Negative Cash FlowOngoing negative operating and free cash flow indicate structural cash burn outside of one-time investing timing. Even with strong liquidity, sustained negative cash flows force reliance on partnerships, milestone receipts, or capital markets, creating execution risk if clinical or collaboration milestones slip.
Modest And Potentially Declining Revenue BaseA small absolute revenue base concentrated in research fees means operating leverage is limited. Shifting focus to internal programs can reduce near-term partner-derived cash inflows, increasing dependency on milestones and liquidity to fund R&D until internal assets mature or new partner deals are secured.
Scientific And Clinical Outcome RiskThe company's value depends on clinical success of internal candidates and partner programs. Blinded MAD results, limited demographic diversity, and small tolerability signals create execution risk: negative or ambiguous Phase II/I data would materially reduce milestone prospects and downstream royalties.
AbCellera Biologics News
8QQ FAQ
What was Abcellera Biologics, Inc.’s price range in the past 12 months?
Abcellera Biologics, Inc. lowest stock price was €2.49 and its highest was €7.65 in the past 12 months.
What is Abcellera Biologics, Inc.’s market cap?
Abcellera Biologics, Inc.’s market cap is €1.51B.
When is Abcellera Biologics, Inc.’s upcoming earnings report date?
Abcellera Biologics, Inc.’s upcoming earnings report date is Aug 05, 2026 which is in 4 days.
How were Abcellera Biologics, Inc.’s earnings last quarter?
Abcellera Biologics, Inc. released its earnings results on May 11, 2026. The company reported -€0.121 earnings per share for the quarter, beating the consensus estimate of -€0.148 by €0.027.
Is Abcellera Biologics, Inc. overvalued?
According to Wall Street analysts Abcellera Biologics, Inc.’s price is currently Undervalued.
Does Abcellera Biologics, Inc. pay dividends?
Abcellera Biologics, Inc. does not currently pay dividends.
What is Abcellera Biologics, Inc.’s EPS estimate?
Abcellera Biologics, Inc.’s EPS estimate is -0.12.
How many shares outstanding does Abcellera Biologics, Inc. have?
Abcellera Biologics, Inc. has 305,375,400 shares outstanding.
What happened to Abcellera Biologics, Inc.’s price movement after its last earnings report?
Abcellera Biologics, Inc. reported an EPS of -€0.121 in its last earnings report, beating expectations of -€0.148. Following the earnings report the stock price went down -14.642%.
Which hedge fund is a major shareholder of Abcellera Biologics, Inc.?
Currently, no hedge funds are holding shares in DE:8QQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AbCellera Biologics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€9.12 (80.27% Upside)
€9.12 (80.27% Upside)
Blogger Sentiment
Neutral
DE:8QQ Sentiment 57%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth €83.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
2.73%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.76%
Trailing 12-Months
Company Description
Abcellera Biologics, Inc.
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
8QQ Company Deck
8QQ Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a generally positive clinical and financial picture: compelling interim Phase I data for ABCL635 (favorable tolerability, strong PK/PD and sustained target engagement) with a clear near-term Phase II catalyst (Q3 2026), expanding pipeline progress, and a robust liquidity position (~$655M available including government funding). Headwinds include continued quarterly losses (~$43M), modest current revenue (~$8M) with expected declines in partner-derived research fees, a small potential tolerability signal at the highest dose (900 mg), blinded MAD data limiting full visibility, and remaining scientific/efficacy risk until Phase II readout. Overall, positives (clinical momentum, liquidity, and pipeline cadence) outweigh the negatives, but the company remains dependent on upcoming Phase II and other near-term milestones.View all DE:8QQ earnings summaries8QQ Revenue Breakdown
93.51% Research fees
3.94% Royalty revenue
2.55% Milestone payments
8QQ Stock 12 Month Forecast
Average Price Target
€9.12
▲(80.27% Upside)
Technical Analysis
Syndax Pharmaceuticals
―
Arcus Biosciences
―
Dianthus Therapeutics
―
Edgewise Therapeutics
―
Structure Therapeutics, Inc. Sponsored ADR
―